Congratulations to Sciad Communications’ clients - 2018 in Review
Several of our clients have been recognised this year for their progress and contributions to their respective industries.
- International Trade and Innovation – Queen’s Awards for Enterprise
- 27th – Deloitte UK Technology Fast 50
As well as gaining award recognition, this year has seen a number of our clients secure new funding to continue their research and fund further growth.
- £118,000 – Innovate UK – Develop a new biophysical screening method for G-protein coupled receptors (GPCRs)
- £235,000 – Innovate UK – Evaluate inducible promoter platform in collaboration with Lonza
- £1.9M – Scottish Enterprise – Expand Synpromics’ R&D programmes in gene regulation for cell and gene medicines
- Medicines Manufacturing Grant – Innovate UK – Extend its pilot scale manufacture of patches formulated with its unique TEPI Patch® technology to GMP manufacture for clinical trials
- Innovate UK – Expand network model of the outer wall of Gram-negative bacteria
- $10million – Saudi, Swedish and Korean Investors– Clinical development of revolutionary thermostable vaccines
- $55million – Series B Funding Round – Advance RSV clinical studies into Phase IIa paediatric and adult trials
Three clients have launched new parts of their businesses including a huge scientific/medical research award and new technology to aid scientific reproducibility and collaboration.
British Heart Foundation
- Big Beat Challenge – £30 million award to identify and solve any of the biggest problems in heart and circulatory disease
- Open Access – provides free use of the Scientific Development Environment for next-generation design and publishing of experiments to academics and non-profits
- Peer Science Coin – A new blockchain-based payment token for scientists and academic institutions collaborating on peerwith.com
Working with a range of life science and technology firms, we see a number of exciting projects and cutting edge research. Two of our clients reached successful clinical trial mile stones this year.
- Positive Phase I results – Completion of first clinical safety studies of the TEPI Patch
- Positive phase II results – RV521, an oral RSV fusion inhibitor significantly reduced viral load, reduced total mucus weight and reduced clinical symptoms, compared to placebo